Audentes Plans Gene Therapy Manufacturing Facility

Published 3-7-2020
  • Audentes Therapeutics - Gene Therapy Manufacturing Facility
  • Audentes Therapeutics - Gene Therapy Manufacturing Facility

    Courtesy of Audentes Therapeutics.

Audentes Therapeutics is planning to construct a $109 million gene therapy manufacturing facility in Sanford, N.C. The 135,000-sf project will support the production of genetic medicines based on adeno-associated virus vectors for the treatment of rare neuromuscular diseases. The center is expected to be operational by 2021. Audentes Therapeutics is a subsidiary of Astellas Pharma.